

| | | | | | | | | | |
|--|------------|---------|--------|-----------|-----|----------|------|-------|-------|
| PubMed | Nucleotide | Protein | Genome | Structure | PMC | Taxonomy | OMIM | Books | |
| Search | PubMed | ▼ | for | | | | | Go | Clear |
| Limits Preview/Index History Clipboard Details | | | | | | | | | |

| | | | | | | | | | | |
|---------|----------|---|------|----|---|------|---|---------|------|---|
| Display | Abstract | ▼ | Show | 20 | ▼ | Sort | ▼ | Send to | Text | ▼ |
|---------|----------|---|------|----|---|------|---|---------|------|---|

☐ 1: Biull Eksp Biol Med 1993 Sep;116(9):311-3

[Related Articles, Links](#)

Entrez PubMed

[The mite allergen and allergoid stimulation of histamine secretion by mast cells]

[Article in Russian]

PubMed
Services

Khlgtatian SV, Perova NA, Berzhets VM.

Rat peritoneal mast cells were incubated with serum from highly mite-sensitive patients. It was demonstrated that exposure of passive sensitized mast cells to allergen from mites *Dermatophagoides farinae* induced the release of histamine. Exposure of mast cells to 10 micrograms/ml and 50 micrograms/ml mite allergen resulted in an increase of histamine secretion to 48% of the basal level. The allergoid (formaldehyde-modified mite allergen) had poor histamine-releasing activity compared to allergen. The allergoid (50 micrograms/ml) induced a 2.5-fold decrease in histamine release. The allergen at the same concentrations and the same release as allergen in dose 0.1 microgram/ml.


Related
Resources

PMID: 7509651 [PubMed - indexed for MEDLINE]

| | | | | | | | | | | |
|---------|----------|---|------|----|---|------|---|---------|------|---|
| Display | Abstract | ▼ | Show | 20 | ▼ | Sort | ▼ | Send to | Text | ▼ |
|---------|----------|---|------|----|---|------|---|---------|------|---|

[Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)
[Department of Health & Human Services](#)
[Freedom of Information Act](#) | [Disclaimer](#)

Feb 19 2003 14:38:47



| | | | | | | | | |
|--|------------|---------|--------|-----------|-----|----------|------|-------|
| PubMed | Nucleotide | Protein | Genome | Structure | PMC | Taxonomy | OMIM | Books |
| Search PubMed | ▼ for | | | | | | Go | Clear |
| Limits Preview/Index History Clipboard Details | | | | | | | | |

| | | | | | | | | | |
|---------|----------|---|----------|---|------|---|---------|------|---|
| Display | Abstract | ▼ | Show: 20 | ▼ | Sort | ▼ | Send to | Text | ▼ |
|---------|----------|---|----------|---|------|---|---------|------|---|

☐ 1: Schweiz Rundsch Med Prax 1990 Apr 3;79(14):430-6

[Related Articles, Links](#)

Entrez PubMed

[Hyposensitization in pollinosis. Results of a 3-year controlled study with 2 depot-allergoid grass pollen extracts: aluminum hydroxide-adsorbed allergoid and tyrosine-adsorbed allergoid]

[Article in German]

PubMed
Services

Muhlethaler K, Wuthrich B, Peeters AG, Terki N, Girard JP, Frank E.

Dermatologische Klinik, Universitat Zurich.

Related
Resources

For controlled hyposensitization treatment over a period of three years 36 patients with confirmed grass pollen sensitization had been selected in 1986 and randomly distributed to receive preseasonal injection therapy: 23 patients were treated with an average of seven AGD (aluminium-adsorbed allergoid) injections, and 13 patients had received six TA (tyrosine-adsorbed allergoid) injections. Evaluation of the trial data collected during three years of preseasonal treatment showed the following results of tolerance and efficacy: Systemic side-reactions registered during therapy were only mild and transient and occurred in the average after 3% of the AGD injections and after 10% of the TA injections. Local reactions over 5 cm diameter were registered after 7% in the AGD group and after 9% in the TA group. Before therapy there was no significant difference (p greater than 0.05) between the groups; after three years of therapy the AGD injections had resulted in a mean net rise of specific IgG of 220% (significant, $p = 0.001$); during the same time, TA injections had resulted in a final net increase of 10% (not significant, p greater than 0.05). Both treatment forms did not lead to any statistically relevant changes of specific IgE values. After three years of hyposensitization treatment, patients of both groups had improved; but an advantage was documented for patients treated with AGD on the basis of scores for objective assessment as well as for registered symptom and medication scores.

Publication Types:

- Clinical Trial
- Randomized Controlled Trial

PMID: 2188335 [PubMed - indexed for MEDLINE]